$890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit."
You can find more data on corporate lobbying on Quiver Quantitative.
NBIX Insider Trading Activity
NBIX insiders have traded $NBIX stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KEVIN CHARLES GORMAN has made 0 purchases and 6 sales selling 166,543 shares for an estimated $24,358,762.
- JUDE ONYIA (Chief Scientific Officer) has made 0 purchases and 5 sales selling 83,186 shares for an estimated $10,808,937.
- WILLIAM H RASTETTER sold 30,000 shares for an estimated $3,305,952
- STEPHEN A SHERWIN sold 13,831 shares for an estimated $1,613,922
- KYLE GANO (Chief Executive Officer) has made 0 purchases and 4 sales selling 5,079 shares for an estimated $650,505.
- MATT ABERNETHY (Chief Financial Officer) has made 0 purchases and 4 sales selling 4,821 shares for an estimated $610,967.
- EIRY ROBERTS (Chief Medical Officer) has made 0 purchases and 5 sales selling 4,655 shares for an estimated $596,752.
- DARIN LIPPOLDT (Chief Legal Officer) has made 0 purchases and 4 sales selling 4,345 shares for an estimated $553,852.
- ERIC BENEVICH (Chief Commercial Officer) has made 0 purchases and 4 sales selling 4,341 shares for an estimated $551,966.
- JULIE COOKE (Chief Human Resources Officer) has made 0 purchases and 5 sales selling 3,991 shares for an estimated $529,946.
- DAVID W. BOYER (Chief Corp. Affairs Officer) has made 0 purchases and 4 sales selling 3,589 shares for an estimated $460,056.
- INGRID DELAET (Chief Regulatory Officer) has made 0 purchases and 5 sales selling 2,973 shares for an estimated $390,963.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NBIX Hedge Fund Activity
We have seen 253 institutional investors add shares of NBIX stock to their portfolio, and 323 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX added 2,518,199 shares (+83.5%) to their portfolio in Q1 2025, for an estimated $278,512,809
- CITADEL ADVISORS LLC removed 1,649,081 shares (-65.0%) from their portfolio in Q1 2025, for an estimated $182,388,358
- JPMORGAN CHASE & CO added 1,299,812 shares (+94.8%) to their portfolio in Q1 2025, for an estimated $143,759,207
- DSM CAPITAL PARTNERS LLC removed 932,595 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $103,145,007
- AQR CAPITAL MANAGEMENT LLC removed 822,261 shares (-43.3%) from their portfolio in Q1 2025, for an estimated $90,942,066
- WELLINGTON MANAGEMENT GROUP LLP added 640,556 shares (+44.0%) to their portfolio in Q1 2025, for an estimated $70,845,493
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 627,000 shares (+72.7%) to their portfolio in Q1 2025, for an estimated $69,346,200
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NBIX Analyst Ratings
Wall Street analysts have issued reports on $NBIX in the last several months. We have seen 12 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 07/09/2025
- RBC Capital issued a "Outperform" rating on 06/02/2025
- Piper Sandler issued a "Overweight" rating on 05/06/2025
- Needham issued a "Buy" rating on 05/06/2025
- Canaccord Genuity issued a "Buy" rating on 05/06/2025
- Guggenheim issued a "Buy" rating on 05/06/2025
- Evercore ISI Group issued a "Outperform" rating on 04/24/2025
To track analyst ratings and price targets for NBIX, check out Quiver Quantitative's $NBIX forecast page.
NBIX Price Targets
Multiple analysts have issued price targets for $NBIX recently. We have seen 15 analysts offer price targets for $NBIX in the last 6 months, with a median target of $163.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $163.0 on 07/21/2025
- Corinne Johnson from Goldman Sachs set a target price of $182.0 on 07/10/2025
- Ashwani Verma from UBS set a target price of $174.0 on 07/09/2025
- Brian Abrahams from RBC Capital set a target price of $145.0 on 06/02/2025
- Evan Seigerman from BMO Capital set a target price of $115.0 on 05/06/2025
- Yatin Suneja from Guggenheim set a target price of $165.0 on 05/06/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $160.0 on 05/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
